UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 380

Sortiert nach

Behandlung früher und intermediärer Stadien des Hodgkin-Lymphoms

Die Onkologie, 2022-10, Vol.28 (10), p.879-888

2022

Volltextzugriff (PDF)

Value of bone marrow biopsy in Hodgkin lymphoma patients staged by FDG PET: results from the German Hodgkin Study Group trials HD16, HD17, and HD18

Annals of oncology, 2018-09, Vol.29 (9), p.1926-1931

2018

Volltextzugriff (PDF)

PET-2-guided escalated BEACOPP for advanced nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the randomized German Hodgkin Study Group HD18 study

Annals of oncology, 2021-06, Vol.32 (6), p.807-810

2021

Volltextzugriff (PDF)

Impact of individualized treatment on recovery from fatigue and return to work in survivors of advanced-stage Hodgkin’s lymphoma: results from the randomized international GHSG HD18 trial

Annals of oncology, 2024-03, Vol.35 (3), p.276-284

2024

Volltextzugriff (PDF)

Prognostic impact of gross tumor volume during radical radiochemotherapy of locally advanced non-small cell lung cancer—results from the NCT03055715 multicenter cohort study of the Young DEGRO Trial Group

Strahlentherapie und Onkologie, 2021-05, Vol.197 (5), p.385-395

2021

Volltextzugriff (PDF)

HIGH RATE OF METABOLIC COMPLETE RESPONSE AFTER LOW DOSE RADIOTHERAPY AND OBINUTUZUMAB IN EARLY STAGE FOLLICULAR LYMPHOMA: INITIAL RESULTS OF THE GAZAI STUDY (GLA 2018‐3)

Hematological oncology, 2023-06, Vol.41 (S2), p.218-220

2023

Volltextzugriff (PDF)

Impact of PET‐2 guided treatment de‐escalation on time‐to‐recovery from cancer‐related fatigue in advanced stage Hodgkin Lymphoma: results from the GHSG HD18 study

Hematological oncology, 2023-06, Vol.41 (S2), p.355-356

2023

Volltextzugriff (PDF)

Toxicities at one year follow‐up in patients with advanced stage classical Hodgkin Lymphoma: results from the randomized phase III HD21 trial by the German Hodgkin Study Group

Hematological oncology, 2023-06, Vol.41 (S2), p.363-364

2023

Volltextzugriff (PDF)

Correction to: Prognostic impact of gross tumor volume during radical radiochemotherapy of locally advanced non-small cell lung cancer—results from the NCT03055715 multicenter cohort study of the Young DEGRO Trial Group

Strahlentherapie und Onkologie, 2021-06, Vol.197 (6), p.560-561

2021

Volltextzugriff (PDF)

Checkpoint inhibitors and radiation treatment in Hodgkin’s lymphoma: New study concepts of the German Hodgkin Study Group

Strahlentherapie und Onkologie, 2017-02, Vol.193 (2), p.95-99

2017

Volltextzugriff (PDF)

S203: ABSCOPAL EFFECT OF RADIOTHERAPY AND NIVOLUMAB IN RELAPSED OR REFRACTORY HODGKIN LYMPHOMA: PRE‐PLANNED INTERIM ANALYSIS OF THE INTERNATIONAL GHSG PHASE II AERN TRIAL

HemaSphere, 2022-06, Vol.6, p.104-105

2022

Volltextzugriff (PDF)

Quality Assurance of Involved Field Radiation Therapy Within the HD13 and HD14 Trial (early stages) of the German Hodgkin Study Group

International journal of radiation oncology, biology, physics, 2015-11, Vol.93 (3), p.E449-E449

2015

Volltextzugriff (PDF)

Aktueller Stellenwert der Positronenemissionstomographie beim Hodgkin-Lymphom

Der Onkologe, 2014-05, Vol.20 (5), p.429-440

2014

Volltextzugriff (PDF)

New quality assurance program integrating “modern radiotherapy” within the German Hodgkin Study Group

Strahlentherapie und Onkologie, 2017-02, Vol.193 (2), p.100-108

2017

Volltextzugriff (PDF)

Relapse Analysis After Radiation Therapy of PET-Positive Residual Tumors of Patients With Advanced Stage Hodgkin Lymphoma Treated in the HD15 Trial of the German Hodgkin Study Group (GHSG)

International journal of radiation oncology, biology, physics, 2013-10, Vol.87 (2), p.S5-S6

2013

Volltextzugriff (PDF)

Quality control of involved field radiotherapy in the HD 13 and HD 14 trials: Report of the radiotherapy panel of the German Hodgkin Study Group (GHSG)

Strahlentherapie und Onkologie, 2017-02, Vol.193 (2), p.109-115

2017

Volltextzugriff (PDF)

Acute bacterial otitis externa: efficacy and safety of topical treatment with an antibiotic ear drop formulation in comparison to glycerol treatment

Current medical research and opinion, 2011-04, Vol.27 (4), p.871-878

2011

Volltextzugriff (PDF)

EBEACOPP WITH OR WITHOUT RITUXIMAB IN INTERIM‐PET‐POSITIVE ADVANCED‐STAGE HODGKIN LYMPHOMA: UPDATED RESULTS OF THE INTERNATIONAL, RANDOMIZED PHASE 3 GHSG HD18 TRIAL

Hematological oncology, 2017-06, Vol.35 (S2), p.65-65

2017

Volltextzugriff (PDF)

Quality control of involved-field radiotherapy for patients with early stage Hodgkin’s lymphoma based on a central prospective review: Comparison of the results between two study generations of the German Hodgkin Study Group

Strahlentherapie und Onkologie, 2012-08, Vol.188 (8), p.660-665

2012

Volltextzugriff (PDF)

OC-0624 variance-based sensitivity analysis (SA) for the evaluation of margin concepts in radiotherapy

Radiotherapy and oncology, 2023-05, Vol.182, p.S514-S515

2023

Volltextzugriff (PDF)

Concordance in the interpretation of PET after chemotherapy in advanced stage Hodgkin lymphoma

Nuclear medicine, 2015-01, Vol.54 (6), p.241

2015

Volltextzugriff (PDF)

Quality Analysis of Radiation Therapy for Hodgkin Lymphoma in the HD 16/17 Trials: A Final Report By the Reference Radiation Oncology Panel of the German Hodgkin Study Group

International journal of radiation oncology, biology, physics, 2023-10, Vol.117 (2), p.S62-S62

2023

Volltextzugriff (PDF)

Therapie des Hodgkin-Lymphoms in frühen und intermediären Stadien

Onkologie (Heidelberg, Germany), 2018-04, Vol.24 (4), p.303-314

2018

Volltextzugriff (PDF)

OS03.3.A Characterization of long-term metabolic changes of irradiated brain metastases using serial dynamic FET PET imaging

Neuro-oncology (Charlottesville, Va.), 2021-09, Vol.23 (Supplement_2), p.ii6-ii6

2021

Volltextzugriff (PDF)

PH-0525: Radio-immunotherapy versus immunotherapy alone – tolerance and adverse events

Radiotherapy and oncology, 2020-11, Vol.152, p.S287-S288

2020

Volltextzugriff (PDF)

1 – 25 von 380

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(51)
Mit Volltextzugriff
(368)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Behandlung früher und intermediärer Stadien des Hodgkin-Lymphoms

Value of bone marrow biopsy in Hodgkin lymphoma patients staged by FDG PET: results from the German Hodgkin Study Group trials HD16, HD17, and HD18

PET-2-guided escalated BEACOPP for advanced nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the randomized German Hodgkin Study Group HD18 study

Impact of individualized treatment on recovery from fatigue and return to work in survivors of advanced-stage Hodgkin’s lymphoma: results from the randomized international GHSG HD18 trial

Prognostic impact of gross tumor volume during radical radiochemotherapy of locally advanced non-small cell lung cancer—results from the NCT03055715 multicenter cohort study of the Young DEGRO Trial Group

HIGH RATE OF METABOLIC COMPLETE RESPONSE AFTER LOW DOSE RADIOTHERAPY AND OBINUTUZUMAB IN EARLY STAGE FOLLICULAR LYMPHOMA: INITIAL RESULTS OF THE GAZAI STUDY (GLA 2018‐3)

Impact of PET‐2 guided treatment de‐escalation on time‐to‐recovery from cancer‐related fatigue in advanced stage Hodgkin Lymphoma: results from the GHSG HD18 study

Toxicities at one year follow‐up in patients with advanced stage classical Hodgkin Lymphoma: results from the randomized phase III HD21 trial by the German Hodgkin Study Group

Correction to: Prognostic impact of gross tumor volume during radical radiochemotherapy of locally advanced non-small cell lung cancer—results from the NCT03055715 multicenter cohort study of the Young DEGRO Trial Group

Checkpoint inhibitors and radiation treatment in Hodgkin’s lymphoma: New study concepts of the German Hodgkin Study Group

S203: ABSCOPAL EFFECT OF RADIOTHERAPY AND NIVOLUMAB IN RELAPSED OR REFRACTORY HODGKIN LYMPHOMA: PRE‐PLANNED INTERIM ANALYSIS OF THE INTERNATIONAL GHSG PHASE II AERN TRIAL

Quality Assurance of Involved Field Radiation Therapy Within the HD13 and HD14 Trial (early stages) of the German Hodgkin Study Group

Aktueller Stellenwert der Positronenemissionstomographie beim Hodgkin-Lymphom

New quality assurance program integrating “modern radiotherapy” within the German Hodgkin Study Group

Relapse Analysis After Radiation Therapy of PET-Positive Residual Tumors of Patients With Advanced Stage Hodgkin Lymphoma Treated in the HD15 Trial of the German Hodgkin Study Group (GHSG)

Quality control of involved field radiotherapy in the HD 13 and HD 14 trials: Report of the radiotherapy panel of the German Hodgkin Study Group (GHSG)

Acute bacterial otitis externa: efficacy and safety of topical treatment with an antibiotic ear drop formulation in comparison to glycerol treatment

EBEACOPP WITH OR WITHOUT RITUXIMAB IN INTERIM‐PET‐POSITIVE ADVANCED‐STAGE HODGKIN LYMPHOMA: UPDATED RESULTS OF THE INTERNATIONAL, RANDOMIZED PHASE 3 GHSG HD18 TRIAL

Quality control of involved-field radiotherapy for patients with early stage Hodgkin’s lymphoma based on a central prospective review: Comparison of the results between two study generations of the German Hodgkin Study Group

OC-0624 variance-based sensitivity analysis (SA) for the evaluation of margin concepts in radiotherapy

Concordance in the interpretation of PET after chemotherapy in advanced stage Hodgkin lymphoma

Quality Analysis of Radiation Therapy for Hodgkin Lymphoma in the HD 16/17 Trials: A Final Report By the Reference Radiation Oncology Panel of the German Hodgkin Study Group

Therapie des Hodgkin-Lymphoms in frühen und intermediären Stadien

OS03.3.A Characterization of long-term metabolic changes of irradiated brain metastases using serial dynamic FET PET imaging

PH-0525: Radio-immunotherapy versus immunotherapy alone – tolerance and adverse events

Suchergebnisse filtern